跳至主要内容
临床试验/PACTR201110000335351
PACTR201110000335351已完成未知

Role of P-glycoprotein inhibitor in children with interactable epilepsy

yasmin galal0 个研究点目标入组 30 人开始时间: 2011年10月27日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
5 Year(s) 至 15 Year(s)(—)
性别
All

入选标准

  • Age 5 - 15 years old
  • Probable or definite localization-related, primary generalized or symptomatic generalized epilepsy that is medically-refractory, as defined by treatment failure of at least 2 anti-epilepsy drugs at standard doses, despite medication compliance as determined by the treating neurologist. Epileptic patients are considered controlled if they are seizure free for more than six months.
  • Ability of the patient or gaurdian to understand the concept of a placebo-controlled clinical trial

排除标准

  • Any patient with pre-existing cardiac condition.
  • Low blood pressure as regard to the patient age, below 25th percentiles
  • Known hypersensitivity to Verapamil or any component of the formulation.
  • Patient with co-existing renal or hepatic illness

研究者

发起方
yasmin galal

相似试验